Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.

GV-backed cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Tigermed took part in a round that will support clinical progression of a 3D Medicines product pipeline that includes oncology candidate envafolimab.

Merck Group, Bristol Myers-Squibb and Novo-backed cancer drug developer Galecto has filed to go public weeks after it last funding round.

Novo remains the largest shareholder in the endocrine disorder drug developer, which went public in an upsized offering.

Relx and Telus-backed TigerConnect has now raised $149m in equity and debt financing for its healthcare messaging and collaboration platform.

Eli Lilly is to exit the genetic sequencing system provider Readcoor in a cash-and-share acquisition by 10x Genomics. This is one of the relatively few exits we have seen in this space over the past decade.

Corvus spinoff Angel has secured series A funding from investors including Tigermed, Betta Pharmaceuticals and Hisun Pharmaceuticals.

Cambrian Biopharma co-led a $28.5m round for cancer immunotherapy developer Sensei Biotherapeutics with venture capital firm H&S Ventures.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.